Siver Andreas Moestue1, Else Marie Huuse1,
Evita Lindholm2, Beathe Sitter1, Gunhild Mari Mlandsmo2,
Olav Engebrten2, Ingrid Susann Gribbestad1
1Department of Circulation and Medical
Imaging, Norwegian University of Science and Technology, Trondheim, Norway; 2Department
of Tumor Biology, Institute for Cancer Research, Oslo, Norway
Using
HR MAS MRS, the changes in choline metabolite concentrations in xenograft
models of luminal-like and basal-like breast cancer were studied following
treatment with bevacizumab and/or doxorubicin. The choline metabolism in the
two models responded differently to the treatments.
Keywords